Drug candidates fail – most of them, in fact. And a significant proportion fail because of poor pharmacokinetics, or the safety risks were unacceptable. Accordingly, integrated ADME-Tox studies are designed to characterize these parameters early, enabling the identification and de-risking of compounds with inadequate bioavailability, metabolic instability, or toxicity signals before progression into costly late-stage failures.
Here are the questions we hear most often when it comes drug discovery, answered directly.
Why should ADME-Tox be integrated early in drug discovery?
The answer is partly economic, partly scientific – and the scientific reason is the stronger one.
Screening for ADME liabilities at lead identification stage is inexpensive relative to the cost of discovering those liabilities later. A compound found to be metabolically unstable early enough can be redesigned, while a compound found to have the same liability after advancing through development studies represents sunk cost and delayed programmes.
But the more consequential benefit is structural. When small molecule ADME data feeds into medicinal chemistry in real time – during the design-make-test cycle – chemists can modify a compound to address pharmacokinetic weaknesses without sacrificing the potency and selectivity they’ve worked to build. Once a lead is locked, those options narrow considerably.
ADME-Tox is often framed as a downstream checkpoint that compounds must pass; however, it is more accurately treated as a multidimensional optimization parameter, to be balanced alongside pharmacological activity from the earliest stages of structure evaluation.
What does an ADME-Tox profile actually tell you about a compound?
An ADME-Tox profile maps how a compound behaves in a biological system across five dimensions: how well it’s absorbed, where it distributes, how it’s metabolised, how it is excreted and whether it – or its metabolites – causes harm in the process.
Together, those parameters determine whether a compound with the right pharmacological activity can function as a drug. A metabolically unstable compound may not reach its target at therapeutic concentrations, another with poor membrane permeability may not reach it at all, while one that inhibits key cytochrome P450 (CYP) enzymes creates drug-drug interaction (DDI) liability that could make it clinically unworkable in a polypharmacy setting.
The data describe what happens, sure, but they also inform every subsequent decision about candidate selection, dose, formulation, and development path – and they do so most usefully when they arrive early enough to act on.
How does the Admescope platform approach drug-drug interaction assessment?
DDI risk arises when a compound alters the activity of enzymes or transporters involved in the disposition of co-administered drugs. This can lead to changes in exposure, either through inhibition or induction of metabolic pathways. The most clinically significant DDIs are mediated by CYP enzymes, which are involved in the metabolism of ~70–80% of small molecule drugs in clinical use. Given that patients are frequently on polypharmacy regimens, potential drug-drug interactions should be assessed early, with consideration of the co-medications most likely to be used within the intended patient population.
Early DDI screening focuses on CYP inhibition and induction assays. These can be run cost-efficiently to flag compounds with meaningful CYP liability before significant resources are committed to further development. However, it’s also good to bear in mind the risk of the compound being a DDI object, and hence, its metabolic routes should also be assessed.
No single assay provides a definitive answer, but a combination of inhibition, induction, and understanding the metabolic fate, generate the profile required to make informed go/no-go decisions at the point in development where they’re most actionable.
Drug-induced liver injury (DILI) remains a leading cause of drug attrition – how do you screen for it early?
DILI is one of the more difficult safety liabilities to predict, partly because it encompasses multiple distinct mechanistic pathways rather than a single failure mode. These include oxidative stress, mitochondrial dysfunction, hepatocellular fat accumulation (steatosis), phospholipid accumulation (phospholipidosis), bile flow disruption via efflux transporter inhibition and the formation of reactive metabolites capable of covalently binding cellular proteins.
Our DILIscope panel was developed specifically to address this mechanistic breadth at the early screening stage. It uses multiparametric imaging endpoints to assess multiple DILI-relevant cellular responses simultaneously – which provides more mechanistic resolution than single-endpoint assays, and more efficiently than running each parameter in isolation.
Efflux transporter inhibition assays targeting hepatocyte bile acid transporters add further specificity. Impaired bile flow is a key DILI mechanism that standard cytotoxicity assays would miss. Reactive metabolite trapping assays identify compounds that form chemically reactive species – a mechanism linked to both direct hepatotoxicity and immune-mediated adverse reactions.
The combination doesn’t eliminate DILI risk; that ultimately requires clinical data. What it does is substantially narrow the range of mechanistic uncertainty before those studies begin.
The field has shifted towards new modalities. How does ADME-Tox adapt for peptides, oligonucleotides, PROTACs, and ADCs?
Small molecules and biomolecules behave differently, and those differences are significant for how ADME data is generated and interpreted.
- Peptides typically show poor oral bioavailability and rapid proteolytic degradation – challenges that standard permeability and metabolic stability assays aren’t designed to directly capture.
- Oligonucleotides distribute heavily to liver and kidney and are cleared via nuclease-mediated pathways rather than CYP enzymes, making standard DDI screens largely uninformative and cell-based distribution assays considerably more relevant.
- PROTACs introduce bifunctional complexity: their larger molecular weight challenges conventional permeability models, and their mechanism of action – targeted protein degradation via the ubiquitin-proteasome system – creates pharmacodynamic/ pharmacokinetic relationships that standard exposure-response frameworks don’t fully describe.
- For ADCs, the ADME challenge sits at the intersection of the antibody, the linker and the small-molecule payload – payload release kinetics and metabolite profiling require assays adapted to the conjugate, not to the component parts in isolation.
These modalities still need rigorous ADME-Tox characterisation and they’ve expanded what that characterisation needs to cover. Applying small-molecule frameworks to biomolecule programmes generates incomplete data, and the evidence for interpreting novel modality ADME results remains less established than for traditional small molecules. That gap is closing, but it needs ADME scientists to stay on top of how this field is changing.
What does the future of ADME-Tox look like?
Two developments are likely to reshape routine practice over the next five to ten years.
The first is AI and machine learning for ADME prediction. Computational models for metabolic stability, permeability and toxicity have existed for years, but with limited or varying predictive accuracy. Training on larger and more chemically diverse datasets, including proprietary assay data from laboratory platforms, is beginning to produce models with meaningful predictive value for well-characterised parameters. There’s no question around whether these models are going to become routine, it’s just a matter of how quickly they generate the training data required to extend reliably to novel modalities.
The second is the progressive displacement of animal studies by complex in vitro systems. Spheroid and organoid cultures, organ-on-a-chip microfluidic platforms (microphysiological systems, or MPS) and advanced co-culture hepatocyte models are improving reproducibility and mechanistic depth. Regulatory agencies in both the EU and US (such as the FDA’s iterations on the Modernization Act) have begun signalling openness to these platforms as partial replacements for some in vivo studies. Progress is incremental, but the direction is consistent.
Both developments require ADME scientists to build proficiency in data science and computational methods alongside wet-lab expertise – something more and more ADME-Tox programmes require.
What’s the most important thing a drug discovery team can do when designing their ADME-Tox strategy?
Bringing ADME expertise into the programme before candidate selection and connect it directly to the medicinal chemistry team.
In our experience, the compounds that reach IND tend to be the ones where ADME and chemistry were optimised together from the start – not sequentially. Detecting an ADME liability in a compound that still carries optimal potency and selectivity creates a specific, addressable problem. Detecting it after those properties have been locked creates a much harder one.
About the author
Dr. Sanna-Mari Aatsinki is Head of Drug-Drug Interactions and In Vitro Toxicology at Admescope, a Symeres company. With deep expertise in in vitro toxicology, drug-drug interaction assessment, and mechanistic safety evaluation, she supports drug discovery teams in identifying and mitigating risk early through integrated ADME-Tox strategies.
Related services
Resources we think you'll love
Webinar | On-demand
Embracing scientific complexity to mitigate toxicity issues and development risks while advancing toward the clinic
Watch this on-demand webinar to explore how scientific depth and an integrated approach to drug development can help teams address increasingly complex development challenges more effectively.
Infographics
Map your molecule’s next move with the Symeres developability roadmap
Is your molecule ready for development? Explore a practical roadmap to help you identify risks, prioritise studies, and move toward IND or IMPD readiness with greater clarity.
Blog
Three Signs Your Synthetic Route Will Collapse at Scale
A synthetic route that performs well at gram scale can fail abruptly during scale-up, where heat transfer, impurity pathways and operational variability expose hidden weaknesses. This article outlines three early red flags that signal a route may not withstand manufacturing conditions — and how identifying them early can prevent costly rework.
Blog
Lead optimization: what data actually drive decisions?
Lead optimization often stalls not because of a lack of data, but because the available data has not been translated into clear decisions. This article explores how disciplined, decision-led lead optimization strategies help discovery teams reduce uncertainty, focus experiments, and progress programs more predictably.
Blog
When slowing chemistry speeds programs up
This article explores how disciplined, hypothesis-driven lead optimization can produce clearer SAR, reduce development risk, and help small-molecule programs progress more efficiently toward a clinical candidate.
Blog
When a clean PK profile is actually a warning sign
A clean pharmacokinetics profile is often seen as a green light. But in practice, overly tidy PK data can hide analytical artefacts, non-linear behaviour, or poorly understood clearance mechanisms that surface later at significant cost.
Blog
CDMO red flags you can’t ignore: Communication breakdowns
Communication breakdowns rarely start as major problems, but small gaps in coordination can quietly slow progress and erode trust in CDMO partnerships.
Blog
CDMO red flags you can’t ignore: Capacity constraints and resource stretch
Part 4: When “Too Busy” Becomes a Business Risk Even the most capable CDMO cannot deliver high-quality work if it is stretched too thin. As demand for outsourcing continues to rise across the life sciences sector, many CDMOs are operating near or beyond capacity. For pharma and biotech companies, this creates a silent but serious […]
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Part 3: Could Regulatory Misalignment Be Delaying Your Submission? A CDMO can have the best scientists, excellent facilities, and strong technical execution, yet still fall short when it comes to regulatory alignment. This disconnect between scientific performance and regulatory readiness is one of the most damaging red flags in drug development as it could delay […]
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Selecting the right CDMO is one of the most important choices a biotech or pharma team will make. The right partner helps you move efficiently toward IND or IMPD, safeguard quality, and anticipate regulatory needs before they become roadblocks. The wrong one can mean delays, rising costs, and lost momentum. At Exemplify BioPharma, a Symeres company, […]
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Part 2: Why “Scale-Up” Isn’t Just a Bigger Batch Transitioning a process from discovery scale to GMP manufacturing is almost never straightforward. What runs smoothly at 100 milligrams in the lab can behave very differently at the kilogram scale. Yet too many programs falter because the complexity of this transition is underestimated or treated as […]
Blog
O.N.E Symeres: A practical approach to real-world drug development
No drug development program runs perfectly. Chemistry misbehaves, funding shifts, and timelines tighten. But what defines a reliable partner is how they respond. O.N.E Symeres is the framework we use to keep projects moving through uncertainty: openness, nimbleness, and expertise.
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Part 1: Is an Undefined Scope Putting Your Project at Risk? Selecting the right CDMO is one of the most important decisions in drug development. Yet even experienced biotechs and pharma companies can find themselves trapped in projects where the initial excitement gives way to frustration, and one of the most common culprits is a […]
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
By combining automation, data-driven design, and deep synthetic expertise, Symeres is redefining how chemists generate and optimize compound libraries, bringing speed, scalability, and creativity to modern drug discovery.
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
From the classical and Dutch resolution methods to preferential crystallization and deracemization, learn the best ways to obtain your desired purity!
Whitepaper
IND & IMPD enabling developability roadmap
Drug discovery and development is a complex and iterative process that involves the identification, design, development, testing, and approval of new pharmaceutical drugs for use in patients. It encompasses a series of scientific, regulatory, and commercial activities aimed at discovering and bringing safe and effective medicines to the market. A key milestone in this process […]
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Unnatural amino acids enable groundbreaking advancements in drug discovery, biomaterials, and peptide design by introducing novel chemical functionalities that enhance stability, specificity, and bioactivity. This whitepaper highlights Symeres’ expertise in synthesizing unnatural amino acids, including side-chain modifications, N-functionalization, and cyclic variants, for applications in pharmaceuticals, diagnostics, and materials science. Utilizing advanced techniques like biocatalysis and […]
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Our experience in overcoming scaleup challenges and harnessing the benefits of non-noble-metal catalysis makes Symeres the CRO of choice for challenging steps, such as the Ullmann reaction.
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
A comprehensive overview of nitrosamine risk assessment, including potential formation, scavenging, and analysis, is described here.
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Here at Symeres, we have our new ‘Solid-State Center of Excellence’, and in this whitepaper we describe how we utilize our expertise and novel innovation to further our solid-state capabilities.
Whitepaper
Stable isotope-labeled compounds
Discover how Symeres applies advanced synthetic chemistry and ADME expertise to design, produce, and study stable isotope-labelled compounds that enhance precision in drug development.
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Learn how Symeres combines advanced chemistry platforms and deep discovery expertise to design and expand the SymeGold library, driving more efficient high-throughput screening and smarter hit identification.
Interviews
Insights into drug discovery and development 2025
Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?
Interviews
Interview with the computer-aided drug design (CADD) department
Our Computer Aided Drug Design department supports our clients' drug discovery projects with some of the best (predictive) software.
Interviews
Meet the Organix Director, Mario Gonzalez
We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.
Interviews
Interview with the new Managing Director of Symeres Groningen
On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site.
Interviews
An interview with Yadan Chen and Paul O’Shea
We are pleased to introduce the founders of Symeres’ daughter company Exemplify in New Jersey: Yadan Chen, CEO, and Paul O’Shea, Chief Scientific Officer. Who are they? What do they stand for? And how does Exemplify fit with Symeres?
Interviews
An interview with Anu Mahadevan and Paul Blundell
We proudly introduce the founders of Symeres’ daughter company Organix in Boston: Anu Mahadevan, CEO, and Paul Blundell, President at Organix. Who are they? What do they stand for? And how does Organix fit with Symeres?
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Organix, a Symeres company, developed scale up conditions of the synthesis of 25-hydroxy cholesterol 3-monosulfate (sodium salt) from cholesterol. After the protection of the hydroxy group (acetate) and double bond (debromination), the hydroxy group in position 25 was introduced using oxone and trifluoromethylethylketone. Then the 3-hydroxy group and double bond were deprotected, and the resulting […]
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Despite a good part of ADME research in drug discovery and preclinical development can be performed using various in silico or in vitro systems, eventually it becomes necessary to evaluate the pharmacokinetic (PK) profile in animals to elucidate in vivo DMPK properties of the drug candidates.
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Medicinal chemistry is the art of rapidly evolving initial hits to clinical candidates via smart, information driven multiparametric optimization.
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
The webinar by Dr. Edwin Aret of Symeres focuses on advanced strategies for selecting and controlling solid forms of pharmaceutical compounds through crystallization techniques.
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
The webinar by Dr. Martin Strack provides an in-depth exploration of the strategies and considerations involved in developing scalable synthetic routes for Active Pharmaceutical Ingredients (APIs)
Webinar | On-demand
Solid-state chemistry part I: Introduction
This webinar, presented by solid-state expert Edwin Aret, offers an insightful introduction to the field of solid-state chemistry.
Speak with our experts
Let’s discuss how Symeres can support the discovery and development of your next breakthrough